Arthneeti
All Q1 FY27 results →
B

Biocon

Q1 FY27

Biocon Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹349
Market cap₹56.9K Cr
P/E78.3
Updated16 Oct 2026
Read3 min read

What the Q1 FY27 call signalled

0 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexNo capex planned

The short version

Biosimilars business expected to see meaningful acceleration in second half of FY27 with new product launches driving growth (Page 6, 9, 10). Biosimilars business expected to show meaningful acceleration in growth, especially in the second half of FY27, driven by recent launches and expanded manufacturing capacity.

From Biocon's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Moderate growth
  • Biosimilars business expected to see meaningful acceleration in second half of FY27 with new product launches driving growth (Page 6, 9, 10).
  • Generics business showing healthy revenue growth (21% YoY) with new launches like liraglutide contributing; further scale-up expected (Page 7, 10).
  • Continued new product launches planned annually in biosimilars through the end of the decade to sustain growth (Page 17).
  • Insulin franchise expansion supported by manufacturing capacity increase with EMA approval, expected to drive global demand (Page 6).
  • Aflibercept launched in US ophthalmology market with strong growth opportunities anticipated (Page 9, 15).
  • Focus on calibrated profitable growth rather than just market share to ensure sustainable revenue and margin expansion (Page 9, 18).

2 more points from Biocon's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Biocon said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

No capex planned
  • Biocon currently holds a small stake in Bicara.
  • Regarding manufacturing in the USA, Biocon does not plan to increase capital expenditure to establish new facilities or capacities; instead, they focus on partnerships and utilizing existing manufacturing facilities (Page 20).
  • The Biocon Group is looking at having a local manufacturing footprint where needed, primarily through partnerships rather than building new plants (Page 20).

2 more points from Biocon's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Biocon said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Biocon said on order book & pipeline — free account, 30 seconds.

Biocon — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹4.5K Cr, net profit ₹199 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Biocon Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Biocon and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Biocon Q1 FY27 results?

Biosimilars business expected to see meaningful acceleration in second half of FY27 with new product launches driving growth (Page 6, 9, 10). Biosimilars business expected to show meaningful acceleration in growth, especially in the second half of FY27, driven by recent launches and expanded manufacturing capacity.

What is Biocon share price analysis?

Biocon currently shows a below-average growth signal. The stock trades at a P/E of 78.2 with a market cap of ₹56,909 Cr. Investors should review the full earnings analysis for detailed insights.

Is Biocon planning capital expenditure?

Biocon currently holds a small stake in Bicara.

Keep Biocon on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.